STOCK TITAN
  1. Home
  2. News
  3. INCR

Intercure Ltd - INCR STOCK NEWS

Welcome to our dedicated news page for Intercure (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intercure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intercure's position in the market.

News
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
Rhea-AI Summary
InterCure (NASDAQ: INCR) announced preliminary results for the full year of 2023, with estimated annual revenue of NIS 351 million and EBITDA over NIS 50 million. Despite challenges from a terrorist attack and war in Gaza, the company expects sequential double-digit quarterly growth in 2024. InterCure continues to expand globally and launch products in Germany, showing resilience and profitability in a tough year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
News
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
Rhea-AI Summary
InterCure (INCR) expects to launch products in Germany following the passing of the 'CannG' Cannabis Act, which will make prescribing medical cannabis easier and more cost-effective. The company anticipates significant growth in the German medical cannabis market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
none
-
News
InterCure Provides an Update Regarding Nir Oz Facility
Rhea-AI Summary
InterCure Ltd. provides an update on the status of its facility in Southern Israel after being impacted by the war situation declared by the Israeli government. The Company is working on restoring the site and seeking compensation for damages caused by the conflict. Despite challenges, InterCure remains committed to supporting patients and the community while focusing on its mission to bring relief through medical cannabis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
News
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
Rhea-AI Summary
InterCure Ltd. (NASDAQ: INCR) has entered into a share purchase agreement to acquire Leon Pharm Ltd., a leading pharmacy chain specializing in dispensing medical cannabis in Israel. The acquisition is expected to expand InterCure's market-leading distribution network in line with the new medical cannabis reform announced by the Israeli Ministry of Health. The transaction is anticipated to be accretive to the company's business model and is subject to certain closing conditions, including regulatory approvals. The CEO, Alexander Rabinovich, expressed confidence in the acquisition's ability to serve the unique needs of patient communities in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
acquisition
-
News
InterCure Wins Cannolam Arbitration Proceeding
Rhea-AI Summary
InterCure Ltd., the leading medical cannabis company in Israel, has concluded an arbitration process in which the arbitrator ruled in favor of the company on most claims. The arbitrator determined that Cannolam owes InterCure significant amounts, and as a result, InterCure now holds 100% of the shares in Cannolam. Cannolam is the leading pharmacy chain specializing in dispensing pharmaceutical-grade cannabis and has the exclusive right to use the 'Cookies' brand in Israel and other territories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
InterCure Provides an Update Regarding the Security Situation in Israel
Rhea-AI Summary
InterCure Ltd. addresses the impact of the security situation in Israel on the company and its employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
none
News
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
Rhea-AI Summary
InterCure achieves record revenues of NIS 209 million ($75 million) for H1 2023, representing YOY growth of over 14%. Adjusted EBITDA of NIS 30 million ($11 million) and cash from operations of NIS 35 million ($13 million) in Q2. Strong balance sheet with over NIS 116 million ($42 million) cash and financial assets of NIS 71 million ($25 million). Sustained market share growth and collaboration agreement with Mike Tyson's brand. New Israeli medical cannabis regulations expected to increase demand. Lawsuit and separation process with Cannolam have negative impact. Commercial launches of GMP products in UK and Germany expected in Q4 2023 and Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
-
News
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News
InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
Stock INCR logo
Intercure Ltd

Nasdaq:INCR

INCR Rankings

#4119 Ranked by Market Cap
#5290 Ranked by Stock Gains
N/A Ranked by Dividends

INCR Stock Data

107.55M
32.21M
35.8%
10.92%
0.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Herzliya

About INCR

intercure (dba canndoc) (nasdaq: incr) (tsx: incr.u) (tase: incr) is the leading, profitable, and fastest growing cannabis company outside of north america. canndoc, a wholly owned subsidiary of intercure, is israel’s largest licensed cannabis producer and one of the first to offer good manufacturing practices (gmp) certified and pharmaceutical-grade medical cannabis products. intercure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of north america. for more information, visit: http://www.intercure.co.